PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1250861
PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1250861
‘Non-antibiotic Bacterial Therapeutics ’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for non-antibiotic therapeutic substances that can treat bacterial infections that are resistant to many or most available antibiotics. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift in treatment options.